GPC
ARLZ

Glacier Peak Capital’s Aralez Pharmaceuticals Inc. ARLZ Stock Holding History

Glacier Peak Capital’s Portfolio ARLZ Stock Details ARLZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-155,200
Closed -$332K – 37
2017
Q1 		$332K Buy
155,200
+52,800
+52% +$198K 0.3% 30
2016
Q4 		$452K Buy
102,400
+56,400
+123% +$268K 0.26% 72
2016
Q3 		$223K Buy
+46,000
New +$210K 0.38% 22

Other funds holding ARLZ

PCM
PAR Capital Management Boston, Massachusetts $3.45B AUM 28.5% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return

Glacier Peak Capital's ARLZ Position: Q2 2017 in Review

Glacier Peak Capital sold out of Aralez Pharmaceuticals Inc. (ARLZ) in Q2 2017, closing a stake of 155,200 shares — an estimated $332K sold.

Glacier Peak Capital first reported a position in ARLZ in Q3 2016 and held it in 3 quarters. The position peaked at $452K in Q4 2016. 72 funds tracked by Wall St. Rank hold ARLZ as of Q2 2017.

  • Glacier Peak Capital reported no remaining Aralez Pharmaceuticals Inc. position as of Q2 2017 after selling out during the quarter.
  • Glacier Peak Capital sold 155,200 Aralez Pharmaceuticals Inc. shares in Q2 2017, an estimated $332K.
  • Glacier Peak Capital first reported a position in Aralez Pharmaceuticals Inc. in Q3 2016 and held it in 3 quarters.
  • Glacier Peak Capital's Aralez Pharmaceuticals Inc. position peaked at $452K in Q4 2016.
  • 72 funds tracked by Wall St. Rank held Aralez Pharmaceuticals Inc. as of Q2 2017.

Based on Glacier Peak Capital's 13F filing for Q2 2017, filed 4 Aug 2017.